Oncosec Medical (ONCS) KEYNOTE-695 Phase 2b Data Shows Partial Response in Two of Nine Patients, One Had Stable Disease

November 6, 2018 8:07 AM

OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS) today reported preliminary data from KEYNOTE-695, a global, multicenter Phase 2b, open-label trial of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found